322P - Evaluation of chemotherapy response score as a prognostic factor in advanced epithelial ovarian cancer: A prospective single centre study

Background

There is limited evidence regarding the prognostic value of the three-tier chemotherapy response score (CRS) in advanced epithelial ovarian cancer (EOC). We aimed to evaluate the impact of CRS on survival in advanced EOC.

Methods

This prospective single-centre study included consecutive women with stage IIIC-IV EOC who underwent interval debulking surgery (IDS) after neoadjuvant chemotherapy (NACT) at Tata Medical Center between March 2021 and June 2022. Clinical characteristics, progression-free survival (PFS), and overall survival (OS) were compared between the CRS groups.

Results

Among the 102 women treated with NACT followed by IDS, CRS 1 was found in 16 (15.7%), CRS 2 in 66 (64.7%), and CRS 3 in 20 (19.6%). Age, stage, and BRCA status were not different across CRS groups. The patients with CRS 3 had significantly longer PFS than the other CRS groups (median PFS 17 months, 19.8 months, and not reached for CRS 1, 2, and 3, respectively, P = 0.001). Estimated OS was also significantly longer in those with CRS 3 (median OS 22.2 months, 33 months, and not reached for CRS 1, 2, and 3, respectively, P = 0.035). The PFS and OS differences remained statistically significant in univariate and multivariate analyses.

Conclusions

Chemotherapy response score 3 was associated with improved survival in advanced EOC treated with NACT. The prognostic value of CRS can be used in future studies of response-adapted adjuvant or maintenance treatment in advanced EOC.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.